Free shipping on all orders over $ 500


Cat. No. M22476
Exarafenib Structure


Size Price Availability Quantity
25mg USD 1350  USD1350 In stock
50mg USD 2200  USD2200 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Exarafenib (KIN-2787) is a highly selective, potent, next-generation, pan-RAF inhibitor with activity across BRAF and RAS mutant human tumor cell models. Exarafenib has anticancer activity by suppression of downstream MAPK pathway signaling. KIN-2787 in combination with binimetinib demonstrated significant combination benefit in NRAS mutant melanoma models.

Chemical Information
Molecular Weight 521.58
Formula C26H34F3N5O3
CAS Number 2639957-39-2
Solubility (25°C) DMSO 90 mg/mL
Storage 4°C, protect from light, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Enrico Tiacci, et al. N Engl J Med. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia

[2] Ralf Gutzmer, et al. Lancet. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

[3] Claus Garbe, et al. Recent Results Cancer Res. Vemurafenib

[4] Reinhard Dummer, et al. Lancet Oncol. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

[5] Claus Garbe, et al. Recent Results Cancer Res. Vemurafenib

Related Raf Products
BRAF inhibitor 

BRAF inhibitor is a B-Raf inhibitor.

B-Raf IN 11 

B-Raf IN 11 (ZINC72115182) is a selective B-RafV600E inhibitor (IC50=76 nM), shows selectivity for B-RafV600E over B-RafWT with selectivity of 3.1-fold. B-Raf IN 11 can be used in colorectal cancer research[1]


KG5 is an orally active dual PDGFRβ and B-Raf allosteric inhibitor. KG5 also inhibits Flt3, KIT and c-Raf. KG5 has anticancer, antiangiogenic activities.

Raf inhibitor 2 

Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research.


HG6-64-1 is a potent and selective B-Raf inhibitor, with an IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells.

Abmole Inhibitor Catalog

Keywords: Exarafenib, KIN-2787 supplier, Raf, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.